Reagent rental figures shock Italian government
This article was originally published in Clinica
Executive Summary
More than 14,000 instruments had been installed in Italian laboratories under reagent rental plan agreements as of December 31st, 1994, according to a report in Il Sole-24 Ore. Evidence from records of materials used with 7,779 instruments showed that over 5,200 had been supplied on condition that the health authority purchased materials or reagents from the same equipment supplier. These preliminary results of a survey conducted by a Health Ministry committee into the extent of reagent rental plans indicate wider usage than expected. The figures do not include Sicily, where magistrates first began investigating the legality of this business practice.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.